Person · CIK 1593283
Anne Clem Whitaker
Director at Alkermes and Icon
Earlier: Orasure Technologies, Mallinckrodt, Caladrius Biosciences, Cree, Valeant Pharmaceuticals International and Synta Pharmaceuticals
Sold on Form 4$2.2M
Noticed on Form 144$138K
Bought on Form 4$1.8M
Companies8
Holdings now
As reported after the latest Form 3, 4 or 5 at each company.
How these figures work
Options and RSUs are from the latest filing that lists them; earlier grants may also be held. Holdings can be out of date when a person stops filing.
| Company | Security | Held | Shares or units | As of |
|---|---|---|---|---|
| Alkermes ALKS | Non Qualified Stock Option (Right to Buy) exercise $41.45, expires Oct 7, 2036, into Ordinary Shares | Directly | 17,998 | Oct 7, 2026 · Filing · EDGAR |
| Alkermes ALKS | Restricted Stock Unit Award into Ordinary Shares | Directly | 7,239 | Oct 7, 2026 · Filing · EDGAR |
| Icon ICLR | Ordinary Shares | Directly | 891 | Aug 11, 2026 · Filing · EDGAR |
| Icon ICLR | Restricted Share Units into Ordinary Shares | Directly | 1,324 | Aug 10, 2026 · Filing · EDGAR |
| Orasure Technologies | Common Stock | Directly | 23,840 | May 16, 2023 · Filing · EDGAR |
| Caladrius Biosciences | Common Stock | Directly | 182,635 | Jan 10, 2022 · Filing · EDGAR |
| Cree | COMMON STOCK | Directly | 11,274 | Nov 5, 2020 · Filing · EDGAR |
| Valeant Pharmaceuticals International | Common Stock, no par value | Directly | 158,544 | Dec 5, 2016 · Filing · EDGAR |
| Valeant Pharmaceuticals International | Restricted Share Units | Directly | 127,455 | Jul 20, 2015 · Filing · EDGAR |
| Synta Pharmaceuticals | Common Stock | Directly | 500,000 | Sep 2, 2014 · Filing · EDGAR |
Sold and noticed by quarter
Sold (Form 4) Noticed (Form 144) Bought (Form 4)
Quarterly totals as a table
| Quarter | Sold (Form 4) | Noticed (Form 144) | Bought (Form 4) |
|---|---|---|---|
| Q3 2026 | $138K | $138K | — |
| Q4 2020 | $2M | Not machine-readable | — |
| Q1 2016 | $19K | Not machine-readable | — |
| Q3 2015 | $53K | Not machine-readable | — |
| Q2 2015 | — | — | $1.8M |
| Q1 2015 | $22K | Not machine-readable | — |
Form 144 notices went onto EDGAR as structured data on April 13, 2023. Earlier notices were filed on paper and cannot be read here, so those quarters show no noticed amount.
Planned sales (Form 144) and the sales that followed
Each Form 144 notice of a planned sale, grouped by broker and 10b5-1 plan, with the Form 4 sales we matched to it.
How we match
A Form 144 is a notice of a planned sale by an affiliate. SEC Tracker matches each notice to Form 4 sales by the same person at the same company within 90 days of the notice, up to the shares noticed. The match is our inference, not something either filing states.
| Notice date | Noticed | Planned sale | Outcome | Links |
|---|---|---|---|---|
| Icon ICLR · Morgan Stanley Smith Barney · No 10b5-1 plan stated · 1 notice | ||||
| Aug 11, 2026 | 841 · ~$138K | Aug 11, 2026 | Sold as noticed Sold 841 in 4 sales, Aug 11 to Aug 11 · $138K Form 4 | Filing · EDGAR |
| Sales without a matching Form 144 · 6 sales No matching Form 144 found. Not every sale needs one: small sales and sales by people who are not affiliates are exempt. | ||||
| — | — | — | Notice not machine-readable Mallinckrodt: Sold 21,087 at $0.13 on Nov 6, 2020 · $3K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Cree: Sold 25,248 at $67.87 on Nov 5, 2020 · $1.7M | Filing · EDGAR |
| — | — | — | Notice not machine-readable Cree: Sold 4,000 at $68.35 on Nov 5, 2020 · $273K | Filing · EDGAR |
| — | — | — | Notice not machine-readable Cree: Sold 623 at $30.00 on Feb 16, 2016 · $19K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Cree: Sold 1,994 at $26.74 on Sep 3, 2015 · $53K (10b5-1 plan) | Filing · EDGAR |
| — | — | — | Notice not machine-readable Cree: Sold 624 at $35.09 on Jan 22, 2015 · $22K (10b5-1 plan) | Filing · EDGAR |
Every transaction, by company
Each Form 3, 4 and 5 transaction in plain words, newest first.
How these figures work
Values are shares times the price each filing states; grants, exercises and gifts usually state no price. Held after is what the filing reports was held once the transaction was done, directly or through the named holder.
Icon ICLR Director · filings 2026 to 2026 · sold $138K · $138K noticed on Form 144
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Aug 11, 2026 | Open-market or private sale | −88 | $162.72 | $14K | 1,644 direct | Filing · EDGAR |
| Aug 11, 2026 | Open-market or private sale | −96 | $163.77 | $16K | 1,548 direct | Filing · EDGAR |
| Aug 11, 2026 | Open-market or private sale | −590 | $164.47 | $97K | 958 direct | Filing · EDGAR |
| Aug 11, 2026 | Open-market or private sale | −67 | $165.51 | $11K | 891 direct | Filing · EDGAR |
| Aug 10, 2026 | Option or RSU exercised or converted | +1,732 | 1,732 direct | Filing · EDGAR | ||
| Aug 10, 2026 | Option or RSU exercised or converted Restricted Share Units | −1,732 | 0 direct | Filing · EDGAR | ||
| Aug 10, 2026 | Grant or award from the company Restricted Share Units | +1,324 | 1,324 direct | Filing · EDGAR |
Orasure Technologies Director · filings 2021 to 2023
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| May 16, 2023 | Shares withheld for tax or exercise price | −2,323 | $5.30 | $12K | 23,840 direct | Filing · EDGAR |
| May 15, 2023 | Shares withheld for tax or exercise price | −4,400 | $5.62 | $25K | 26,163 direct | Filing · EDGAR |
| May 16, 2022 | Grant or award from the company | +20,000 | $5.25 | $105K | 30,563 direct | Filing · EDGAR |
| Nov 8, 2021 | Grant or award from the company | +10,563 | $9.94 | $105K | 10,563 direct | Filing · EDGAR |
Mallinckrodt Director · filings 2018 to 2022 · sold $3K
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Nov 6, 2020 | Open-market or private sale | −21,087 | $0.13 | $3K | 0 direct | Filing · EDGAR |
| May 13, 2020 | Shares withheld for tax or exercise price | −8,729 | $2.96 | $26K | 21,087 direct | Filing · EDGAR |
| May 15, 2019 | Shares withheld for tax or exercise price | −8,527 | $15.21 | $130K | 10,420 direct | Filing · EDGAR |
| May 15, 2019 | Grant or award from the company | +19,396 | 29,816 direct | Filing · EDGAR | ||
| May 16, 2018 | Grant or award from the company | +18,947 | 18,947 direct | Filing · EDGAR |
Caladrius Biosciences Director · filings 2020 to 2022
Cree Director · filings 2013 to 2020 · sold $2.1M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Nov 5, 2020 | Option or RSU exercised or converted | +4,000 | $57.36 | $229K | 40,522 direct | Filing · EDGAR |
| Nov 5, 2020 | Open-market or private sale | −4,000 | $68.35 | $273K | 36,522 direct | Filing · EDGAR |
| Nov 5, 2020 | Open-market or private sale | −25,248 | $67.87 | $1.7M | 11,274 direct | Filing · EDGAR |
| Nov 5, 2020 | Option or RSU exercised or converted NONQUALIFIED STOCK OPTION (RIGHT TO BUY) | −4,000 | 0 direct | Filing · EDGAR | ||
| Sep 1, 2020 | Grant or award from the company | +2,652 | 36,522 direct | Filing · EDGAR | ||
| Sep 1, 2019 | Grant or award from the company | +3,217 | 33,870 direct | Filing · EDGAR | ||
| Sep 1, 2018 | Grant or award from the company | +3,566 | 30,653 direct | Filing · EDGAR | ||
| Sep 1, 2017 | Grant or award from the company | +7,033 | 27,087 direct | Filing · EDGAR | ||
| Sep 1, 2016 | Grant or award from the company | +6,429 | 20,054 direct | Filing · EDGAR | ||
| Feb 16, 2016 | Sale under a 10b5-1 plan | −623 | $30.00 | $19K | 13,625 direct | Filing · EDGAR |
| Sep 3, 2015 | Sale under a 10b5-1 plan | −1,994 | $26.74 | $53K | 14,248 direct | Filing · EDGAR |
| Sep 1, 2015 | Grant or award from the company | +6,674 | 16,242 direct | Filing · EDGAR | ||
| Jan 22, 2015 | Sale under a 10b5-1 plan | −624 | $35.09 | $22K | 9,568 direct | Filing · EDGAR |
| Jan 21, 2015 | Grant or award from the company | +553 | $33.87 | $19K | 10,192 direct | Filing · EDGAR |
| Oct 22, 2014 | Grant or award from the company | +687 | $27.27 | $19K | 9,639 direct | Filing · EDGAR |
| Sep 2, 2014 | Grant or award from the company | +4,244 | 8,952 direct | Filing · EDGAR | ||
| Sep 2, 2014 | Grant or award from the company | +4,244 | 8,952 direct | Filing · EDGAR | ||
| Aug 13, 2014 | Grant or award from the company | +278 | $44.81 | $12K | 4,708 direct | Filing · EDGAR |
| Apr 23, 2014 | Grant or award from the company | +245 | $51.01 | $12K | 4,430 direct | Filing · EDGAR |
| Jan 22, 2014 | Other acquisition or disposition (see the filing) | +185 | $67.30 | $12K | 4,185 direct | Filing · EDGAR |
| Dec 2, 2013 | Grant or award from the company | +4,000 | 4,000 direct | Filing · EDGAR | ||
| Dec 2, 2013 | Grant or award from the company NONQUALIFIED STOCK OPTION (RIGHT TO BUY) | +4,000 | 4,000 direct | Filing · EDGAR |
Valeant Pharmaceuticals International EVP, Company Group Chairman · filings 2015 to 2016 · bought $1.8M
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Dec 5, 2016 | Shares withheld for tax or exercise price | −6,012 | $18.00 | $108K | 158,544 direct | Filing · EDGAR |
| Aug 2, 2016 | Shares withheld for tax or exercise price | −834 | $23.54 | $20K | 158,544 direct | Filing · EDGAR |
| May 12, 2016 | Grant or award from the company | +37,935 | 165,390 direct | Filing · EDGAR | ||
| Jul 20, 2015 | Grant or award from the company | +7,500 | 127,455 direct | Filing · EDGAR | ||
| May 26, 2015 | Open-market or private purchase | +5,000 | $235.00 | $1.2M | 5,000 direct | Filing · EDGAR |
| May 26, 2015 | Open-market or private purchase | +2,500 | $234.00 | $585K | 7,500 direct | Filing · EDGAR |
| May 13, 2015 | Grant or award from the company | +112,455 | 119,955 direct | Filing · EDGAR |
Synta Pharmaceuticals President and CEO · filings 2014 to 2015
| Date | Transaction | Shares | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|
| Mar 2, 2015 | Grant or award from the company Employee Stock Option (Right to Buy) | +100,000 | 100,000 direct | Filing · EDGAR | ||
| Sep 2, 2014 | Grant or award from the company | +500,000 | 500,000 direct | Filing · EDGAR | ||
| Sep 2, 2014 | Grant or award from the company Employee Stock Option (Right to Buy) | +500,000 | 500,000 direct | Filing · EDGAR | ||
| Sep 2, 2014 | Grant or award from the company Employee Stock Option (Right to Buy) | +250,000 | 250,000 direct | Filing · EDGAR |
All 47 Forms 3, 4, 5 and 144
| Filed | Form | Company | Links |
|---|---|---|---|
| Oct 9, 2026 | Form 4 | Alkermes ALKS | Filing · EDGAR |
| Sep 18, 2026 | Form 3 | Alkermes ALKS | Filing · EDGAR |
| Aug 12, 2026 | Form 4 | Icon ICLR | Filing · EDGAR |
| Aug 11, 2026 | Form 144 | Icon ICLR | Filing · EDGAR |
| Mar 18, 2026 | Form 3 | Icon ICLR | Filing · EDGAR |
| May 17, 2023 | Form 4 | Orasure Technologies | Filing · EDGAR |
| Jun 21, 2022 | Form 4 | Mallinckrodt | Filing · EDGAR |
| May 18, 2022 | Form 4 | Orasure Technologies | Filing · EDGAR |
| Jan 12, 2022 | Form 4 | Caladrius Biosciences | Filing · EDGAR |
| Nov 18, 2021 | Form 3 | Orasure Technologies | Filing · EDGAR |
| Nov 10, 2021 | Form 4 | Orasure Technologies | Filing · EDGAR |
| Jan 12, 2021 | Form 4 | Caladrius Biosciences | Filing · EDGAR |
| Nov 10, 2020 | Form 4 | Mallinckrodt | Filing · EDGAR |
| Nov 6, 2020 | Form 4 | Cree | Filing · EDGAR |
| Nov 3, 2020 | Form 4 | Caladrius Biosciences | Filing · EDGAR |
| Nov 3, 2020 | Form 3 | Caladrius Biosciences | Filing · EDGAR |
| Sep 3, 2020 | Form 4 | Cree | Filing · EDGAR |
| May 15, 2020 | Form 4 | Mallinckrodt | Filing · EDGAR |
| Sep 4, 2019 | Form 4 | Cree | Filing · EDGAR |
| May 17, 2019 | Form 4 | Mallinckrodt | Filing · EDGAR |
| Sep 5, 2018 | Form 4 | Cree | Filing · EDGAR |
| May 18, 2018 | Form 4 | Mallinckrodt | Filing · EDGAR |
| May 18, 2018 | Form 3 | Mallinckrodt | Filing · EDGAR |
| Sep 6, 2017 | Form 4 | Cree | Filing · EDGAR |
| Dec 20, 2016 | Form 4/A | Valeant Pharmaceuticals International | Filing · EDGAR |
| Dec 20, 2016 | Form 4 | Valeant Pharmaceuticals International | Filing · EDGAR |
| Dec 7, 2016 | Form 4 | Valeant Pharmaceuticals International | Filing · EDGAR |
| Sep 6, 2016 | Form 4 | Cree | Filing · EDGAR |
| May 16, 2016 | Form 4 | Valeant Pharmaceuticals International | Filing · EDGAR |
| Feb 18, 2016 | Form 4 | Cree | Filing · EDGAR |
| Sep 3, 2015 | Form 4 | Cree | Filing · EDGAR |
| Jul 22, 2015 | Form 4 | Valeant Pharmaceuticals International | Filing · EDGAR |
| Jun 24, 2015 | Form 4 | Valeant Pharmaceuticals International | Filing · EDGAR |
| May 27, 2015 | Form 4 | Valeant Pharmaceuticals International | Filing · EDGAR |
| May 21, 2015 | Form 3 | Valeant Pharmaceuticals International | Filing · EDGAR |
| Mar 4, 2015 | Form 4 | Synta Pharmaceuticals | Filing · EDGAR |
| Jan 23, 2015 | Form 4 | Cree | Filing · EDGAR |
| Jan 23, 2015 | Form 4/A | Cree | Filing · EDGAR |
| Oct 24, 2014 | Form 4 | Cree | Filing · EDGAR |
| Sep 4, 2014 | Form 4 | Synta Pharmaceuticals | Filing · EDGAR |
| Sep 4, 2014 | Form 3 | Synta Pharmaceuticals | Filing · EDGAR |
| Sep 3, 2014 | Form 4 | Cree | Filing · EDGAR |
| Aug 15, 2014 | Form 4 | Cree | Filing · EDGAR |
| Apr 25, 2014 | Form 4 | Cree | Filing · EDGAR |
| Jan 24, 2014 | Form 4 | Cree | Filing · EDGAR |
| Dec 4, 2013 | Form 4 | Cree | Filing · EDGAR |
| Dec 4, 2013 | Form 3 | Cree | Filing · EDGAR |
Every figure is as filed with the SEC on Forms 3, 4, 5 and 144. Holdings are the amounts reported after each person's latest filing at each company and can be out of date. Matching a Form 144 notice to Form 4 sales is SEC Tracker's inference from owner, company, dates and share counts, not something the filings state. Not investment advice. Not affiliated with the U.S. SEC.